Page last updated: 2024-11-06

levobunolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Levobunolol is a non-selective beta-blocker used in the treatment of open-angle glaucoma and ocular hypertension. It is a synthetic compound with a chiral center, and the levorotatory enantiomer (levobunolol) is the active form. Levobunolol reduces intraocular pressure by decreasing the production of aqueous humor, the fluid that fills the eye. It works by blocking the action of beta-adrenergic receptors in the eye, which are responsible for stimulating the production of aqueous humor. Levobunolol is typically administered as eye drops. It is studied because it is a safe and effective treatment for glaucoma, a condition that can lead to blindness if left untreated. Levobunolol has been shown to reduce the risk of developing vision loss and improve quality of life for patients with glaucoma.'

Levobunolol: The L-Isomer of bunolol. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

levobunolol : A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

cortistatin J: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID39468
CHEMBL ID1201237
CHEBI ID6438
SCHEMBL ID24095
MeSH IDM0003033
PubMed CID16737543
CHEMBL ID391053
SCHEMBL ID12431714
MeSH IDM0003033

Synonyms (76)

Synonym
BRD-K31812033-003-03-7
ak-beta
gtpl570
l-bunolol
w-6421a
liquifilm
CHEBI:6438 ,
levobunololum
5-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2h)-one
(s)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone
cas-47141-41-3
cas-27912-14-7
NCGC00016801-01
NCGC00016801-02
BSPBIO_000833
PRESTWICK2_000847
BPBIO1_000917
PRESTWICK3_000847
(-)-bunolol
47141-42-4
C07914
levobunolol
DB01210
levobunololum [inn-latin]
ccris 4375
1(2h)-naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, (s)-
levobunolol [inn:ban]
SPBIO_002754
PRESTWICK1_000847
PRESTWICK0_000847
NCGC00016801-03
5-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2h-naphthalen-1-one
levobunolol (inn)
D08115
bunolol, (-)-
bunolol, (s)-
CHEMBL1201237
(-)-levobunolol hydrochloride
AKOS016012242
unii-g6317aoi7k
g6317aoi7k ,
levobunolol [vandf]
levobunolol [mi]
(-)-(s)-5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone
levobunolol [inn]
levobunolol [who-dd]
SCHEMBL24095
IXHBTMCLRNMKHZ-LBPRGKRZSA-N
DTXSID1043833 ,
(s)-5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydronaphthalen-1(2h)-one
5-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalen-1-one
beta-site
Q408556
EN300-18563037
HY-B1035A
CS-0013643
levobunololo
dtxcid9023833
levobunololum (inn-latin)
s01ed03
5-((2s)-3-(tert-butylamino)-2-hydroxypropoxy)-3,4-dihydronaphthalen-1(2h)-one
CHEMBL391053
cortistatin j
AKOS015966941
(-)-cortistatin j
cortistatine j
unii-f69cwm0jqx
10a,12a-epoxybenzo(4,5)cyclohept(1,2-e)inden-9-amine, 1,2,3,3a,4,9,10,11,12,12b-decahydro-3-(7-isoquinolinyl)-n,n,3a-trimethyl-, (3s,3ar,9s,10ar,12as,12br)-
f69cwm0jqx ,
cortistatin j [mi]
(3s,3ar,9s,10ar,12as,12br)-1,2,3,3a,4,9,10,11,12,12b-decahydro-3-(7-isoquinolinyl)-n,n,3a-trimethyl-10a,12a-epoxybenzo(4,5)cyclohept(1,2-e)inden-9-amine
944804-62-0
SCHEMBL12431714
Q27277712
cortistatinj
DTXSID901336421

Research Excerpts

Overview

Levobunolol is a potent non-selective beta-adrenoceptor blocking agent. It is used for the topical treatment of increased intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension.

ExcerptReferenceRelevance
"Levobunolol is a β-blocker drug prescribed for the control and prevention of cardiovascular events, such as individuals with cardiac arrhythmia or a history of myocardial infarction. "( Levobunolol-imprinted polymer: a theoretical study.
Guimarães, L; Maia, PP; Nascimento, CS, 2023
)
3.8
"Levobunolol is a potent non-selective beta-adrenoceptor blocking agent used for the topical treatment of increased intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. "( Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Clissold, SP; Gonzalez, JP, 1987
)
2.17

Effects

ExcerptReferenceRelevance
"Levobunolol has been well tolerated, producing only minor changes in objective and subjective ophthalmic and systemic parameters."( Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Clissold, SP; Gonzalez, JP, 1987
)
1.45

Actions

ExcerptReferenceRelevance
"Levobunolol, known to inhibit aqueous humor inflow in humans, slowed decay."( Noninvasive assessment of aqueous humor turnover in the mouse eye.
Avila, MY; Civan, MM; Mitchell, CH; Stone, RA, 2003
)
1.04

Treatment

ExcerptReferenceRelevance
"Levobunolol-treated eyes but not betaxolol-treated eyes showed a significant drug effect 1 week after discontinuing the drug therapy."( Comparison of a noncardioselective beta-adrenoceptor blocker and a cardioselective blocker in reducing aqueous flow in humans.
Brubaker, RF; Gaul, GR; Will, NJ, 1989
)
1

Toxicity

ExcerptReferenceRelevance
"5% timolol administered once daily are effective and safe in lowering IOP in most patients with ocular hypertension or open-angle glaucoma."( Efficacy and safety of once-daily levobunolol for glaucoma therapy.
Almog, Y; Friedland, BR; Kelley, EP; Lazar, M; LeBlanc, RP; Lee, PF; Mann, C; Novack, GD; Orr, A; Rakofsky, SI, 1989
)
0.56
" Adverse experiences requiring cessation of therapy occurred in an additional 10% of patients."( Levobunolol. A four-year study of efficacy and safety in glaucoma treatment. The Levobunolol Study Group.
, 1989
)
1.72
" Levobunolol and timolol were similarly effective and safe in reducing intraocular pressure in patients with chronic open-angle glaucoma and those with ocular hypertension."( [Comparison of the effectiveness and safety of levobunolol and timolol in ocular hypertension and chronic open-angle glaucoma].
Batoosingh, AL; Freyler, H; Menapace, R; Mordaunt, J; Novack, GD; Skorpik, C, 1988
)
1.44
"While adverse effects are uncommon in patients who are otherwise fit and well, doctors should be aware of the implications of the systemic effects of these drugs, particularly the non-selective types, and particularly in the elderly."( The safety of topical beta-blockers in glaucoma treatment.
Goldberg, I, 1996
)
0.29
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" Application of this method indicated that an azone-containing ophthalmic formulation of levobunolol did not produce better ocular bioavailability than a formulation containing no penetration enhancer."( The effect of azone on ocular levobunolol absorption: calculating the area under the curve and its standard error using tissue sampling compartments.
Burke, PJ; Tang-Liu, DD, 1988
)
0.79
" The systemic bioavailability ranged from 61% for atenolol to 100% for timolol."( Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit.
Kompella, UB; Lee, VH; Lee, YH, 1993
)
0.29
" A better understanding of the mechanisms involved in transcorneal permeation could lead to improvements in drug dosage forms or the development of drug delivery devices which enhance the ocular bioavailability of drugs."( Theoretical corneal permeation model for ionizable drugs.
Cheng, YL; Friedrich, SW; Saville, BA, 1993
)
0.29

Dosage Studied

We conducted a randomized, double-masked, dose-response study of the ocular hypotensive effect of the beta-adrenergic blocker, levobunolol. The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of betaxolol are reviewed.

ExcerptRelevanceReference
"Female beagles dosed once with encapsulated 14C-bunolol (10 mg/kg) excreted 61% of the isotope in urine in 24 hr."( Bunolol metabolism by dogs: identification of basic metabolites and their conjugates.
Di Carlo, FJ; Greenough, RC; Leinweber, FJ, 1977
)
0.26
"In an attempt to increase patient compliance with a dosing regimen, prescriptions for topical solutions of glaucoma medication were refilled using the C Cap, a memory aid designed to help patients to remember to instill the medication as prescribed."( Effectiveness of the C Cap in promoting prescription refill compliance among patients with glaucoma.
Chin, A; Gill, MA; Nakahiro, RK; Okamoto, MP; Sclar, DA; Skaer, TL,
)
0.13
"In a double-masked crossover study, the dose-response relationship for aqueous flow was determined for four concentrations of betaxolol hydrochloride and levobunolol hydrochloride in 19 normal subjects."( Comparison of a noncardioselective beta-adrenoceptor blocker and a cardioselective blocker in reducing aqueous flow in humans.
Brubaker, RF; Gaul, GR; Will, NJ, 1989
)
0.47
" PRA activity was significantly and markedly reduced by both bunolol and metoprolol shortly after dosing at a time when HR was significantly reduced but MBP was not."( Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function.
Antonaccio, MJ; DeForrest, JM; High, J; Sybertz, E, 1986
)
0.27
"Glaucoma is described, and the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of betaxolol and levobunolol in comparison with timolol are reviewed."( Comparison of ophthalmic beta-blocking agents.
Lesar, TS, 1987
)
0.47
" Blood pressure, ventricular rate, and echocardiographically determined ejection fraction, ejection time, and mean rate of circumferential fiber shortening (mVcf) were measured before dosing and at multiple time points during 10 hours after each dose, with subjects maintained in the supine position."( Pharmacodynamic comparison of L-bunolol with propranolol, metoprolol, and placebo.
Bahrmann, H; Greenblatt, DJ; Labedzki, L; Ochs, HR, 1988
)
0.27
" The tpeak was 15 min after dosing and the Cmax was 4 micrograms/mL."( Disposition of levobunolol after an ophthalmic dose to rabbits.
Liu, S; Neff, J; Sandri, R; Tang-Liu, DD, 1987
)
0.63
"We conducted a randomized, double-masked, dose-response study of the ocular hypotensive effect of the beta-adrenergic blocker, levobunolol."( A dose-response study of the effect of levobunolol on ocular hypertension.
Gordon, M; Kass, MA; Partamian, LG, 1983
)
0.74
" A better understanding of the mechanisms involved in transcorneal permeation could lead to improvements in drug dosage forms or the development of drug delivery devices which enhance the ocular bioavailability of drugs."( Theoretical corneal permeation model for ionizable drugs.
Cheng, YL; Friedrich, SW; Saville, BA, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiglaucoma drugAny drug which can be used to prevent or alleviate glaucoma, a disease in which the optic nerve is damaged, resulting in progressive, irreversible loss of vision. It is often, though not always, associated with increased pressure of the fluid in the eye.
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
propanolamine
cyclic ketone
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Levobunolol Action Pathway478

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.94330.001318.074339.8107AID926; AID938
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00080.00020.93267.2000AID625205
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.00050.00000.66359.5499AID625205
Beta-1 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00690.00021.46819.0000AID625204
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.00400.00011.33919.9840AID625204
Beta-3 adrenergic receptorHomo sapiens (human)IC50 (µMol)0.34000.00233.24158.0600AID625206
Beta-3 adrenergic receptorHomo sapiens (human)Ki0.25500.00302.30986.0450AID625206
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)2.90100.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki1.65800.00010.739610.0000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)2.90100.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki1.65800.00031.29679.2440AID625190
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)4.89800.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki2.60200.00000.70488.1930AID625222
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.77300.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.32500.00000.490110.0000AID625223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (78)

Processvia Protein(s)Taxonomy
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID1347018Rat beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID1346312Mouse beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID301297Antiproliferative activity against NHDF cells by WST-8 colorimetric assay2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301293Antiproliferative activity against HUVEC cells by WST-8 colorimetric assay2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301299Selectivity index, ratio of IC50 for HUVEC cells to IC50 for human KB3-1 cells2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301298Selectivity index, ratio of IC50 for HUVEC cells to IC50 for human K562 cells2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301300Selectivity index, ratio of IC50 for HUVEC cells to IC50 for mouse Neuro-2A cells2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301296Antiproliferative activity against mouse Neuro-2A cells by WST-8 colorimetric assay2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301301Selectivity index, ratio of IC50 for HUVEC cells to IC50 for human NHDF cells2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301294Antiproliferative activity against human K562 cells by WST-8 colorimetric assay2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
AID301295Antiproliferative activity against human KB3-1 cells by WST-8 colorimetric assay2007Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21
Structure-activity relationship and biological property of cortistatins, anti-angiogenic spongean steroidal alkaloids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (235)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990128 (54.47)18.7374
1990's62 (26.38)18.2507
2000's27 (11.49)29.6817
2010's15 (6.38)24.3611
2020's3 (1.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.38 (24.57)
Research Supply Index5.80 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index86.77 (26.88)
Search Engine Supply Index2.23 (0.95)

This Compound (48.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials77 (30.56%)5.53%
Trials0 (0.00%)5.53%
Reviews10 (3.97%)6.00%
Reviews0 (0.00%)6.00%
Case Studies30 (11.90%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other135 (53.57%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01504074]50 participants (Actual)Observational2011-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]